ABBV vs NVST
AbbVie vs Envista Holdings — AI-powered side-by-side comparison
VS
NVST
Envista Holdings
70
Buy
| Metric | ABBV | NVST |
|---|
| AI Score |
69
|
70
|
| Price |
$249.34
|
$28.07
|
| P/E Ratio |
70.28×
|
47.58×
|
| ROE |
-129.2%
|
1.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
71.5%
|
55.5%
|
| Debt / Equity |
-11.93×
|
0.52×
|
| Dividend Yield |
2.7%
|
0.0%
|
| RSI (14) |
48.9
|
53.5
|
| Beta |
0.28
|
0.861
|
| Expected Upside |
—
|
+1.9%
|
AI Committee View
Current Innellis committee reasoning for ABBV versus NVST.
NVST leads by 1 points.
NVST scores 70/100 (Buy) versus ABBV at 69/100 (Buy).
ABBV Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.20 across 84 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
NVST Committee View
83% agreement
6 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is p/e of 47.3 is expensive by classic value standards. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- EPS growing 83.6% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 47.3 is expensive by classic value standards — Value
- ROE of only 3.1% -- cheap may mean cheap for a reason — Value